Cochrane Review Group

Drugs and Alcohol

61 systematic reviews in Drugs and Alcohol ask 731 questions. 7.8% have no studies to answer them, 25.4% rest on very low certainty evidence and 28.7% reach moderate or high certainty.

Reviews

Questions

731

current versions

No studies

7.8%

Moderate or high

28.7%

No studies 57 · 7.8%Ungraded 39 · 5.3%Very low 186 · 25.4%Low 239 · 32.7%Moderate 171 · 23.4%High 39 · 5.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Drugs and Alcohol

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Summary of findings table – disulfiram vs naltrexone Continuous abstinence from cocaine (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) · people with cocaine dependence Disulfiram for the treatment of cocaine dependence (2024) · Cochrane	no estimate extracted	NR	No studies
Summary of findings table – disulfiram vs naltrexone Point abstinence (number of participants who were abstinent at the end of the treatment) · people with cocaine dependence Disulfiram for the treatment of cocaine dependence (2024) · Cochrane	no estimate extracted	NR	No studies
Summary of findings table – disulfiram vs naltrexone Dropout for any reason (number of participants who did not complete treatment) · people with cocaine dependence Disulfiram for the treatment of cocaine dependence (2024) · Cochrane	RR 0.86 [0.56, 1.32]	3 studies · 131 participants	Very low
Summary of findings table – disulfiram vs naltrexone Dropout due to adverse events (number of participants who did not complete treatment due to adverse events) · people with cocaine dependence Disulfiram for the treatment of cocaine dependence (2024) · Cochrane	RR 0.5 [0.07, 3.55]	1 study · 8 participants	Very low
Summary of findings table – disulfiram vs naltrexone Any adverse events (number of participants who experienced at least one adverse event) · people with cocaine dependence Disulfiram for the treatment of cocaine dependence (2024) · Cochrane	no estimate extracted	NR	No studies
Summary of findings table – disulfiram vs placebo or no pharmacological treatment Dropout due to adverse events (number of participants who did not complete treatment due to adverse events) · people with cocaine dependence Disulfiram for the treatment of cocaine dependence (2024) · Cochrane	RR 12.97 [0.77, 218.37]	1 study · 67 participants	Very low
Summary of findings table – disulfiram vs placebo or no pharmacological treatment Any adverse events (number of participants who experienced at least one adverse event) · people with cocaine dependence Disulfiram for the treatment of cocaine dependence (2024) · Cochrane	RR 3 [0.35, 25.68]	1 study · 30 participants	Very low
Summary of findings table ‐ Any psychosocial intervention vs treatment Point abstinence, longest · adults with stimulant use disorder Psychosocial interventions for stimulant use disorder (2024) · Cochrane	RR 1.31 [0.86, 1.99]	2 studies · 124 participants	Very low
Summary of findings table ‐ Any psychosocial intervention vs treatment Continuous abstinence, longest · adults with stimulant use disorder Psychosocial interventions for stimulant use disorder (2024) · Cochrane	no estimate extracted	NR	No studies
Summary of findings table ‐ Any psychosocial intervention vs treatment Number of drinks per day ‐ total · stopping or reducing alcohol consumption during pregnancy Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy (2024) · Cochrane	no estimate extracted	2 studies · 157 participants	Very low
Summary of findings table ‐ Any psychosocial intervention vs treatment Adverse events ‐ not measured · stopping or reducing alcohol consumption during pregnancy Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy (2024) · Cochrane	no estimate extracted	NR	No studies
Summary of findings table ‐ Any psychosocial intervention vs treatment Withdrawal signs and symptoms ‐ not measured · stopping or reducing alcohol consumption during pregnancy Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy (2024) · Cochrane	no estimate extracted	NR	No studies

Reviews 61

Opioid antagonists with minimal sedation for opioid withdrawal

Gowing, L, Ali, R, et al. · Cochrane Database of Systematic Reviews · 2017

Drugs and Alcohol

Thinnest evidence

Reviews 61

Opioid antagonists with minimal sedation for opioid withdrawal

Buprenorphine for managing opioid withdrawal

Personalised digital interventions for reducing hazardous and harmful alcohol consumption in community‐dwelling populations

Supervised dosing with a long‐acting opioid medication in the management of opioid dependence

Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs

Alpha₂‐adrenergic agonists for the management of opioid withdrawal

Psychosocial interventions for cannabis use disorder

Antipsychotic medications for cocaine dependence

Motivational interviewing for the prevention of alcohol misuse in young adults

Psychostimulant drugs for cocaine dependence

Brief school‐based interventions and behavioural outcomes for substance‐using adolescents

Dopamine agonists for the treatment of cocaine dependence

Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions

Social norms information for alcohol misuse in university and college students

Anticonvulsants for cocaine dependence

Psychosocial interventions for benzodiazepine harmful use, abuse or dependence

Pharmacological interventions for drug‐using offenders

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

Universal school‐based prevention for illicit drug use

Detoxification treatments for opiate dependent adolescents

Maintenance treatments for opiate ‐dependent adolescents

Anticonvulsants for alcohol dependence

Restricting or banning alcohol advertising to reduce alcohol consumption in adults and adolescents

Methadone at tapered doses for the management of opioid withdrawal

Magnesium for alcohol withdrawal